Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have received an average recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $12.6250.

Several equities analysts have recently weighed in on the stock. Truist Financial set a $12.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. Piper Sandler assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price for the company. B. Riley Financial lifted their target price on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. UBS Group raised their price objective on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Finally, BTIG Research restated a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, March 17th.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently modified their holdings of the company. AXQ Capital LP grew its stake in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after buying an additional 2,481 shares in the last quarter. Deutsche Bank AG grew its stake in Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock worth $149,000 after buying an additional 3,119 shares in the last quarter. Vontobel Holding Ltd. grew its stake in Perspective Therapeutics by 25.0% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after buying an additional 5,000 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares in the last quarter. Finally, Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 6.6% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after buying an additional 6,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Trading Down 1.1%

CATX opened at $3.56 on Thursday. The firm has a 50-day moving average price of $4.10 and a 200-day moving average price of $3.74. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. Equities research analysts anticipate that Perspective Therapeutics will post -1.13 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.